Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 82 out of 100. Biomarkers

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Importance Amyloid-β positron emission tomography (PET) imaging allows in vivo detection of fibrillar plaques, a core neuropathological feature of Alzheimer disease (AD). Its diagnostic utility is still unclear because amyloid plaques also occur in patients with non-AD dementia. Objective To use individual participant data meta-analysis to estimate the prevalence of amyloid positivity on PET in a wide variety of dementia syndromes. Data sources The MEDLINE and Web of Science databases were searched from January 2004 to April 2015 for amyloid PET studies. Study selection Case reports and studies on neurological or psychiatric diseases other than dementia were excluded. Corresponding authors of eligible cohorts were invited to provide individual participant data. Data extraction and synthesis Data were provided for 1359 participants with clinically diagnosed AD and 538 participants with non-AD dementia. The reference groups were 1849 healthy control participants (based on amyloid PET) and an independent sample of 1369 AD participants (based on autopsy). Main outcomes and measures Estimated prevalence of positive amyloid PET scans according to diagnosis, age, and apolipoprotein E (APOE) ε4 status, using the generalized estimating equations method. Results The likelihood of amyloid positivity was associated with age and APOE ε4 status. In AD dementia, the prevalence of amyloid positivity decreased from age 50 to 90 years in APOE ε4 noncarriers (86% [95% CI, 73%-94%] at 50 years to 68% [95% CI, 57%-77%] at 90 years; n = 377) and to a lesser degree in APOE ε4 carriers (97% [95% CI, 92%-99%] at 50 years to 90% [95% CI, 83%-94%] at 90 years; n = 593; P Conclusions and relevance Among participants with dementia, the prevalence of amyloid positivity was associated with clinical diagnosis, age, and APOE genotype. These findings indicate the potential clinical utility of amyloid imaging for differential diagnosis in early-onset dementia and to support the clinical diagnosis of participants with AD dementia and noncarrier APOE ε4 status who are older than 70 years.

What this study adds

Evidence grade: High

This is a pooled review of 377 participants. In Alzheimer's dementia the estimated share with a positive scan fell from 86% at age 50 to 68% at 90 in APOE ε4 non-carriers, and from 97% to 90% in carriers. The authors see potential use in telling dementias apart in early-onset cases and in supporting an Alzheimer's diagnosis in non-carriers over 70; the study is about diagnosis, not treatment.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Ossenkoppele, R., Jansen, W. J., Rabinovici, G. D., Knol, D. L., van der Flier, W. M., van Berckel, B. N., et al. (2015). Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis. JAMA. https://doi.org/10.1001/jama.2015.4669

Vancouver

Ossenkoppele R, Jansen WJ, Rabinovici GD, Knol DL, van der Flier WM, van Berckel BN, et al. Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis. JAMA. 2015. doi:10.1001/jama.2015.4669. PMID: 25988463.

BibTeX

@article{ossenkoppele2015-25988463,
  author  = {Ossenkoppele, R. and Jansen, W. J. and Rabinovici, G. D. and Knol, D. L. and van der Flier, W. M. and van Berckel, B. N. and Scheltens, P. and Visser, P. J. and others},
  title   = {{Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis}},
  journal = {JAMA},
  year    = {2015},
  doi     = {10.1001/jama.2015.4669},
  pmid    = {25988463},
  url     = {https://doi.org/10.1001/jama.2015.4669}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

Amyloid plaques also occur in other dementias, so this meta-analysis pooled individual data on 1,359 people clinically diagnosed with Alzheimer's dementia and 538 with other dementias, and found that a positive amyloid PET scan was associated with diagnosis, age and APOE ε4 status. In Alzheimer's dementia the estimated share with a positive scan fell from 86% at age 50 to 68% at 90 in APOE ε4 non-carriers, and from 97% to 90% in carriers. The authors see potential use in telling dementias apart in early-onset cases and in supporting an Alzheimer's diagnosis in non-carriers over 70; the study is about diagnosis, not treatment.

Study details

How this study scored 82/100
How this study's score is builtJournal tier 10 of 10; Journal's citation record 4 of 4; Study design 12 of 12; Strength of evidence 5 of 5; Peer-review validation 10 of 10; How recent 1 of 5; Sample size 2 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 6 of 7; Citations per year 5 of 5; Impact for its field and year 6 of 6; Cited by studies here 4 of 6; Still being cited 3 of 4; Senior author's track record 4 of 4; Institution's track record 2 of 3; Multicenter collaboration 3 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. Total 82 of 100.82 of 100 points earned18 not earned

Published in a top-tier journal, and it is a meta-analysis pooling many studies. Scored zero for effect reported because the record does not state it.

ComponentPointsWhy
Journal tier 10 / 10 Tier 1 — top-tier general journal (JAMA)
Journal's citation record 4 / 4 JAMA: journal h-index 1,011 (OpenAlex, 2026-10-29)
Study design 12 / 12 A meta-analysis pooling many studies
Strength of evidence 5 / 5 Rated “high” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 1 / 5 2015 — within 20 year(s) of the newest study here
Sample size 2 / 4 377 participants
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 A review of other studies — randomization is not credited here
Times cited 6 / 7 Cited 675 times (OpenAlex, 2026-10-10)
Citations per year 5 / 5 51.9 citations a year over 13 year(s) since 2015
Impact for its field and year 6 / 6 Cited 46.2× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 4 / 6 Cited by 71 other studies in this library
Still being cited 3 / 4 Cited 151 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 4 / 4 Last-listed author David James Brooks: h-index 158 (OpenAlex, whole career)
Institution's track record 2 / 3 University of California, Berkeley: institution h-index 2,012 (OpenAlex)
Multicenter collaboration 3 / 3 OpenAlex lists 45 institution(s) in 13 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 25988463)
Free to read 0 / 2 Behind a paywall — scores zero
Total 82 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 31.

Later studies that cite this one

71 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.

Related studies in Biomarkers from nearby years

Also tagged “machine”

834 studies in the library carry the topic tag “machine”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 834 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Biomarkers

See all studies in Biomarkers →